Paisley

PAISLEY, U.K., June 22, 2011 - Programme aims to demonstrate clinical and economic benefit of DNA sequencing such as: - standardised tests for fast, comprehensive decision making, and - increased pharmaceutical investment in UK-based clinical trials Life Technologies Corporation (NASDAQ: LIFE) today announced that the company has led a successful consortium bidfor a Technology Strategy Boardgrant, in partnership with the Oxford NIHR Biomedical Research Centre, AstraZeneca, and Ortho Biotech Oncology Research & Development unit of Johnson & Johnson Pharmaceutical Research & Development, L.L.C.